

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

**宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;**

**AND**

**(2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following changes to the Board:

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

Mr. Yu Xiaoyong (于曉勇) (“**Mr. Yu**”) has tendered his resignation as a non-executive Director of the Company, with effect from September 30, 2024, in order to devote more time to his other business commitments.

As of the date of this announcement, Mr. Yu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Board would like to express its sincere gratitude to Mr. Yu for his valuable contribution to the Company during his tenure of service.

## PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that, after taking into consideration the recommendation from the nomination committee of the Board, the Board resolved to nominate Ms. Fu Dawei (付大偉) (“**Ms. Fu**”) as a non-executive Director.

The proposed appointment of Ms. Fu is subject to the approval by the Shareholders at an extraordinary general meeting of the Company (the “**EGM**”) by way of ordinary resolution.

The biographical details of Ms. Fu are set out below:

Ms. Fu, aged 47, has over 20 years of experience in investment and technology enterprise management. Ms. Fu joined Shanghai Yongkan Investment Management Co., Ltd. (上海永堪投資管理有限公司) as one of its managing partners in October 2015, and since then, she has been responsible for the day-to-day operations of the fund, which invested in a number of outstanding biopharmaceutical companies, including, among others, Shanghai NewMed Medical Co., Ltd. (上海紐脈醫療科技股份有限公司) (“**Shanghai NewMed**”), Shanghai Novamab Biopharmaceuticals Co., Ltd. (上海洛啟生物醫藥技術有限公司), Shanghai Ennovabio Pharmaceuticals Co. Ltd. (上海軼諾藥業有限公司) and the Company. She served as the deputy general manager of Shanghai Yingshuo Polymeric Materials Co., Ltd. (上海英碩聚合材料股份有限公司), the business license of which was revoked in March 2024, from July 2010 to February 2015. From October 2003 to June 2010, Ms. Fu successively held positions engaged in investment and investment management, in Shanghai Dingjia Ventures Co., Ltd (上海鼎嘉創業投資管理有限公司), Shanghai Minhang Technology Venture Capital Co., Ltd (上海閔行科技創業投資有限公司) and Shiying (Xiamen) Growth Venture Capital Co. Ltd (世盈(廈門)創業投資有限公司).

Ms. Fu obtained a bachelor's degree in accounting and a master's degree in management science and engineering from Shandong University of Science and Technology (山東科技大學) in China in July 1999 and July 2004, respectively. She also obtained a master's degree in business administration from Shanghai Jiao Tong University (上海交通大學) in China in June 2021.

As of the date of this announcement, save as disclosed above, Ms. Fu had confirmed that: (i) she did not have any relationship with any other Directors, supervisors, senior management, substantial Shareholders, or controlling Shareholders of the Company (as respectively defined in the Listing Rules); (ii) she did not have any interest in the shares of the Company within the meaning of Part XV of the SFO; (iii) she did not hold any other positions within the Group; and (iv) she did not hold any directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above, to the best knowledge, information and belief of the Directors having made all reasonable enquiries, there is no other information relating to the proposed appointment of Ms. Fu that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to her appointment that need to be brought to the attention of the Shareholders.

Subject to the approval of the appointment of Ms. Fu at the EGM, the Company will enter into a service contract with Ms. Fu for a term commencing from the date of the approval of the appointment of Ms. Fu at the EGM and ending on the expiry of the term of the first session of the Board, provided that her term of office will not exceed three years, and Ms. Fu is eligible for re-election at the general meeting upon the expiry of her term of office in accordance with the articles of association of the Company. Following the effectiveness of her appointment as the non-executive Director and pursuant to the proposed service contract, Ms. Fu will not be entitled to receive Director's fee for her position as the non-executive Director, after taking into consideration the recommendation from the remuneration committee of the Board, prevailing market conditions and the remuneration policy of the Company.

A circular which includes, among others, the information in relation to the proposed election of Ms. Fu as the non-executive Director, together with the notice of the EGM, will be despatched to the Shareholders (if necessary) and published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.immuneonco.com](http://www.immuneonco.com)) in due course.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Hong Kong, September 30, 2024

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong and Mr. Yu Zhihua as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*